Program
Meropenem
Also written as “meropenem” and “Meropenem plus vaborbactam”.
Its studies are mostly in Sepsis · Enterocolitis, Necrotizing · Bacterial Infections · Pancreatitis · Cellulitis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 40 open or running | phase 4since May 27, 2003 | May 27, 2003 | none ahead |
| The Emmes | 10 open or running | phase 2since Feb 20, 2008 | Feb 20, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 27, 2003First study: phase 4 study in Pancreatitis, Acute NecrotizingNew to PfizerPfizer · NCT00061438 · 240 enrolled · United States, Canada
- Apr 25, 20062 phase 4 studiesPfizer · NCT00318552, NCT00318994
- Feb 6, 2008Phase 3 study in CellulitisPfizer · NCT00619710 · 1,000 enrolled
- Feb 20, 2008The Emmes's first study: phase 2 study in Enterocolitis, NecrotizingNew to The EmmesThe Emmes · NCT00621192 · 200 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial penicillin-binding protein inhibitor”ChEMBL 37, by rule
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT00621192Enterocolitis, Necrotizing · United States | 2 | Completed | The Emmes | Oct 2009 | 200 |
| NCT00619710Cellulitis | 3 | Completed | Pfizer | Dec 2003 | 1,000 |
| NCT00318994Pancreatitis · Colombia | 4 | Completed | Pfizer | Sep 2005 | 6 |
| NCT00318552Sepsis · Hungary | 4 | Completed | Pfizer | Jun 2006 | 160 |
| NCT00061438Pancreatitis, Acute Necrotizing · United States, Canada | 4 | Completed | Pfizer | Dec 2004 | 240 |
How it is read
Names in the registry
- “Meropenem”, 6 entries
- “meropenem”, 3 entries
- “Meropenem plus vaborbactam”, 1 entry
Conditions, from the studies’ own filings
- Sepsis, 2 studies
- Enterocolitis, Necrotizing, 1 study
- Bacterial Infections, 1 study
- Pancreatitis, 1 study
- Cellulitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.